Biomeme Stock

biomeme.comHealthcare / BioTech & PharmaFounded: 2012Funding to Date: $18.33MM

Biomeme is the developer of a platform that transforms your smartphone into a mobile lab for advanced DNA diagnostics and real-time disease surveillance.

Register To Buy and Sell Shares

For more details on private stock price information, financing and valuation for Biomeme, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Biomeme’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Biomeme.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Jesse vanWestrienen
Co-Founder & Lead Biologist
Marc DeJohn
Co-founder & Lead Engineer
Max Perelman
Co-Founder, President, Business Lead and Chief Executive Officer

Biomeme’s stock FAQs


Can you buy Biomeme’s stock?

As Biomeme is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like Biomeme, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge's Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.

How to buy Biomeme’s stock?

To invest in a private company like Biomeme’s through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)
  1. Create a free account to access Forge's marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Biomeme’s stock?

Yes, you may be able to sell your Biomeme’s stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Biomeme’s stock?

If you hold private company shares of Biomeme’s - whether as an employee or an early investor - Forge can help you sell them.
  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Biomeme’s on our platform.
  3. Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.

Is Biomeme’s a public company?

No, Biomeme’s is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Biomeme’s stock price?

Biomeme is a privately held company and therefore does not have a public stock price. However, you may access Biomeme’s private market stock price with Forge Data.

What is Biomeme’s stock ticker symbol?

Biomeme does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Experts discuss the game-changing potential of novel host response-based diagnostics to combat the global challenge of antimicrobial resistance (AMR)

Host response diagnostics, a novel approach that leverages the host-immune response to distinguish between viral and bacterial pathogens, is giving hope in the battle against antimicrobial resistance (AMR). This approach is being led by Biomeme, a company specializing in decentralized molecular diagnostics. The method allows healthcare providers to optimize antibiotic use and combat the rise of AMR.
Updated on: Jul 24, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.